DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin lymphoma.Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.
[R]-DHAP regimen consists of: Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20 Dexamethasone, a glucocorticoid hormone High-dose Ara-C - cytarabine, an antimetabolite; Platinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.
Dosing regimen Drug Dose Mode Days Rituximab 375 mg/m2 IV infusion Day 0 Dexamethasone 40 mg PO qd Days 1-4 High-dose Ara-C - cytarabine 2000 mg/m2 IV infusion over 2 hrs Day 2, every 12 hours Platinol (cisplatin) 100 mg/m2 IV infusion over 24 hrs Day 1
References